secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0001193125-23-044823
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 1.02
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma terminates Recordati license for neffy in EU/UK/MEA; reacquires rights for €3M upfront plus milestones
--------------------------------------------------------------------------------

- Terminated License and Supply Agreement with Recordati Ireland, effective immediately.
- Reacquired exclusive rights to neffy (epinephrine) for EU, UK, Middle East, Africa, Eurasia.
- Pays €3.0M upfront; Recordati eligible for up to €2.0M EMA milestone, €5.0M first commercial sale, up to €5.0M sales milestones.
- Total potential milestone payments to Recordati up to €12.0M.
- ARS regains control of development, manufacturing, regulatory, and commercialization in the territory.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312523044823/0001193125-23-044823-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312523044823/d469633d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-044823

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer